The small molecule FGFR inhibitor infigratinib exerts anti-inflammatory effects and remyelination in a model of multiple sclerosis.

The findings of this proof of concept study demonstrate the therapeutic potential of targeting FGFRs in a disease model of MS. Application of oral infigratinib resulted in anti-inflammatory and remyelinating effects. Thus, infigratinib may have the potential to slow disease progression or even to improve the disabling symptoms of MS.